GoldenGolden
Advanced Search
ZIOPHARM Oncology

ZIOPHARM Oncology

ZIOPHARM Oncology is a biotechnology company developing cancer therapies founded in 2005.

ZIOPHARM Oncology is a biotechnology company developing gene therapy, cell therapy and cancer immunotherapy products that is headquartered in Boston, Massachusetts and was founded in 2005 by Jonathan Lewis.

Ziopharm is developing immunotherapies using Controlled IL-12, which weaponizes the existing immune system and Sleeping Beauty-modified T cells, which introduces new immune system elements to fight cancer.

Products
Controlled IL-12

Controlled IL-12 targets cold tumors, those the exhibit little or no immune system activity, and turns them “hot” by calling in an immune response. As a monotherapy and in combination with checkpoint inhibitors it is being developed to treat brain cancer and the therapeutic potential of other solid tumors is being explored.

The Controlled IL-12 therapeutic introduces the cytokine and immune system regulator, IL-12 plus the drug veledimex as a gene therapy with an Adenoviral vector. IL-12 is expressed in cells under the control of the RheoSwitch Therapeutic System. Veledimex triggers the implanted IL-12 genes to produce IL-12 protein at a controlled dosage, which can also be turned off. IL-12 acts as a beacon to signal T cells to attack and destroy cancerous tissue.

Sleeping Beauty-modified T cells

Sleeping Beauty is a technology Ziopharm is using to develop non-viral cell therapies such as genetically modified chimeric antigen receptors (CARs) and T-cell receptors (TCRs) which target tumor-derived antigens. The technology does not require ex vivo T-cell expansion, so the patient can be treated in a shorter frame of time. Sleeping Beauty can be used to target multiple antigens and has options for blood cancers and solid tumors.

The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) and to target specific antigens in solid tumors and chimeric antigen receptors (CARs). The platform is being advanced with collaboration from the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell.

Timeline

April 28, 2021
Ziopharm Oncology announces that Laurence J.N. Cooper, Scientific Advisor to the Company, was the inaugural presenter at Aldevron's Virtual Breakthrough Speaker Series.
September 12, 2019
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System

Mol Ther. 2016 Jun;24(6):1078-1089

July 2, 2019
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma - Full Text View - ClinicalTrials.gov
June 2019
Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI

(Nasdaq: ZIOP) announced that the investigational new drug (IND) application submitted by the National Cancer Institute (NCI) has received clearance from the U.S. Food and Drug Administration (FDA) for a clinical trial in solid tumors to evaluate T-cell receptor (TCR) T-cell utilizing Ziopharm’s Sleeping Beauty platform.

2005
ZIOPHARM Oncology was founded.

Funding rounds

People

Name
Role
LinkedIn

Charles Yoo

Employee

Eleanor (Ellee) de Groot, Ph.D.

EVP, GM CELL THERAPY

Folake Ogundiran

Employee

Frank R Codispoti

Investor

Hartman King

Investor

Jill Buck

EVP, GM GENE THERAPY

Jonathan Lewis

Founder

Judy Carmody, Ph.D ~ Executive Quality Consultant

Employee

Kyle DiFiore

Investor

Laurence J.N. Cooper, M.D., Ph.D.

CEO

Laurence J.N. Cooper, M.D., Ph.D.

President

Laurence J.N. Cooper, M.D., Ph.D.

EVP, GENERAL COUNSEL, SECRETARY AND CHIEF COMPLIANCE OFFICER

Lynn M. Ferrucci

EVP, HUMAN RESOURCES, FACILITIES, ADMINISTRATION AND IT

Satyavrat (Sath) Shukla, CFA

CFO

Steven Kellman

Investor

Steven Zeppenfeld

Investor

Further reading

Title
Author
Link
Type
Date

Sleeping Beauty Awakens for Genome Engineering

Emma Markham

Web

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System

Web

ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting | ZIOPHARM Oncology, Inc.

Ziopharm

Web

Documentaries, videos and podcasts

Title
Date
Link

Laurence Cooper, CEO, Ziopharm Oncology

November 27, 2017

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
September 28, 2021
FierceBiotech
After 28 days in the CEO post, Kevin Boyle is eliminating more than half of his staff, about 60 people, to extend Ziopharm Oncology's runway. The biotech has run into multiple clinical trial delays for its T-cell receptor program after slashing its glioblastoma asset in the beginning of the year.
Kyle LaHucik
August 30, 2021
FierceBiotech
Kevin S. Boyle has joined cell and gene therapy biotech Ziopharm as CEO. Boyle previously led Kuur Therapeutics and his hiring was done in conjunction with two leadership promotions.
BioSpace
November 24, 2020
BioSpace
Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced that Dr. Brian Schwartz, M.D. has joined the company as Acting Chief Medical Officer and Head of the Scientific Advisory Board (SAB) .
Alex Keown
November 20, 2020
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace
November 17, 2020
BioSpace
Ziopharm Oncology, Inc. ("Ziopharm" or "the Company") (Nasdaq:ZIOP) today announced the appointment of Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer.
November 16, 2020
BioSpace
Ziopharm Oncology Appoints Mary Thistle to Board of Directors - read this article along with other careers information, tips and advice on BioSpace
Reuters Editorial
May 26, 2020
IN
Shanghai Junshi Biosciences Co Ltd said on Tuesday it plans to start clinical studies to test its experimental antibody against COVID-19 in the United States and China in the second quarter of the year, with partner Eli Lilly and Co.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.